Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2312)	6/2/2010 5:38:14 PM
From: Jibacoa	1 Recommendation Respond to of 3722

REGN also closed near its intraday H and above the resistance at the $30 level, albeit it was not able to retest its Feb17 H at $30.51 <g> Volume of 2,161,047 was about 3.6x its ADV bigcharts.marketwatch.com REGN said last month that a single dose of its REGN727 for hypercholesterolemia, lasted for a month and produced a maximum mean reduction in LDL of more than 60%. <g> This was on a PI and there were no serious adverse events reported. The trials have been carried in conjunction with SNY. REGN also said that its REGN475, an analgesic been tried for patients with arthritis, was "generally well tolerated" and it showed improvements in walking pain when studied in 217 patients with osteoarthritis of the knee. The ACTAY is $30.71 But with some good news the stock could get to test its Dec.200 H at $41.69 The Jan2000 H around $58 seems little too far. <g> bigcharts.marketwatch.com Bernard